Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
- Author
- MERIMSKY, Ofer1 ; CHENG, Chi-Kin2 ; SIU-KIE AU, Joseph3 ; VON PAWEL, Joachim4 ; RECK, Martin5
[1] Division of Oncology, Tel Aviv Medical Center, Tel-Aviv 64239, Israel
[2] Department of Oncology, Princess Margaret Hospital, Lai Chi Kok, Hong-Kong
[3] Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong-Kong
[4] Department of Oncology, Asklepios Fachkliniken, 82131 Gauting, Germany
[5] Department of Thoracic Oncology, Krankenhaus Grosshansdorf, 22927 Grosshansdorf, Germany - Source
Oncology reports. 2012, Vol 28, Num 2, pp 721-727, 7 p ; ref : 23 ref
- ISSN
- 1021-335X
- Scientific domain
- Medical oncology
- Publisher
- Spandidos, Athens
- Publication country
- Greece
- Document type
- Article
- Language
- English
- Author keyword
- chemotherapy elderly erlotinib first-line non-small cell lung cancer phase IV
- Keyword (fr)
- Anticancéreux Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Chimiothérapie Efficacité traitement Erlotinib Innocuité Personne âgée Stade avancé Traitement de première intention Traitement Anti-EGFR Cancer Dérivé de la quinazoline Enzyme Homme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Lung cancer Cancerology non-small cell lung carcinoma Chemotherapy Treatment efficiency Erlotinib Harmlessness Elderly Advanced stage First line treatment Treatment Cancer Quinazoline derivatives Enzyme Human Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Quimioterapia Eficacia tratamiento Erlotinib Inocuidad Anciano Estadio avanzado Tratamiento de primera línea Tratamiento Cáncer Enzima Hombre Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26094163
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.3892/or.2012.1824 
https://dx.doi.org/10.3892/or.2012.1824
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.3892\/or.2012.1824\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"721\";s:8:\"\u0000*\u0000epage\";s:3:\"727\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MERIMSKY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ofer\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:14:\"CHENG, Chi-Kin\";i:1;s:18:\"SIU-KIE AU, Joseph\";i:2;s:18:\"VON PAWEL, Joachim\";i:3;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.3892\/or.2012.1824\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"721\";s:8:\"\u0000*\u0000epage\";s:3:\"727\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MERIMSKY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ofer\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:14:\"CHENG, Chi-Kin\";i:1;s:18:\"SIU-KIE AU, Joseph\";i:2;s:18:\"VON PAWEL, Joachim\";i:3;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.3892\/or.2012.1824\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.3892\/or.2012.1824\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"721\";s:8:\"\u0000*\u0000epage\";s:3:\"727\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MERIMSKY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ofer\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:14:\"CHENG, Chi-Kin\";i:1;s:18:\"SIU-KIE AU, Joseph\";i:2;s:18:\"VON PAWEL, Joachim\";i:3;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.3892\/or.2012.1824\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"721\";s:8:\"\u0000*\u0000epage\";s:3:\"727\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MERIMSKY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ofer\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:14:\"CHENG, Chi-Kin\";i:1;s:18:\"SIU-KIE AU, Joseph\";i:2;s:18:\"VON PAWEL, Joachim\";i:3;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.3892\/or.2012.1824\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"721\";s:8:\"\u0000*\u0000epage\";s:3:\"727\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MERIMSKY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Ofer\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:14:\"CHENG, Chi-Kin\";i:1;s:18:\"SIU-KIE AU, Joseph\";i:2;s:18:\"VON PAWEL, Joachim\";i:3;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
